-
公开(公告)号:US20180044434A1
公开(公告)日:2018-02-15
申请号:US15555808
申请日:2016-03-07
申请人: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY , PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY , PHARMA FOODS INTERNATIONAL CO., LTD.
发明人: Mamoru SATO , Michiyuki YAMADA , Satoshi KANAZAWA , Masayoshi TOYOURA , Yuji SHOYA , Kenji SAITO , Chihiro YAMAZAKI
IPC分类号: C07K16/40
CPC分类号: C07K16/40 , A61K39/395 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N9/99 , C12N15/09 , C12Y305/03015 , A61K2300/00
摘要: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
-
公开(公告)号:US20180021429A1
公开(公告)日:2018-01-25
申请号:US15550461
申请日:2016-02-16
发明人: Chie KUDO , Masayoshi TOYOURA , Akiko ISHIDA , Yuji SHOYA , Chihiro YAMAZAKI
IPC分类号: A61K39/395 , C07K16/18
摘要: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.
-